Larimar Therapeutics (LRMR)
4.02
0.00 (0.00%)
Upcoming Events
Latest Headlines
Form 4 Larimar Therapeutics, For: Jul 06 Filed by: Hamilton Thomas Edward
July 8, 2026 4:05 PM - SEC Filing
Larimar Therapeutics (LRMR) Reiterated at Market Outperform by Citizens
July 7, 2026 5:21 AM - StreetInsider
H.C. Wainwright Assumes Larimar Therapeutics (LRMR) at Buy
July 2, 2026 6:05 AM - StreetInsider
Larimar Therapeutics (LRMR) PT Lowered to $5 at Baird
June 30, 2026 6:54 AM - StreetInsider
Form 8-K Larimar Therapeutics, For: Jun 29
June 29, 2026 6:34 AM - SEC Filing
Larimar files first BLA module for Friedreich's ataxia drug
June 29, 2026 6:30 AM - StreetInsider
Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia
June 29, 2026 6:30 AM - Globe NewsWire
Larimar Therapeutics to host investor event on June 29
June 26, 2026 4:05 PM - StreetInsider
Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s Ataxia
June 26, 2026 4:05 PM - Globe NewsWire
JPMorgan Starts Larimar Therapeutics (LRMR) at Overweight
May 27, 2026 1:09 AM - StreetInsider
Form 4 Larimar Therapeutics, For: May 19 Filed by: DEERFIELD MANAGEMENT COMPANY, L.P.
May 20, 2026 8:03 PM - SEC Filing
Form 4 Larimar Therapeutics, For: May 19 Filed by: LEFF JONATHAN S
May 20, 2026 6:04 PM - SEC Filing
Form 4 Larimar Therapeutics, For: May 19 Filed by: SHERMAN JEFFREY W
May 20, 2026 4:31 PM - SEC Filing
Form 4 Larimar Therapeutics, For: May 19 Filed by: Truitt Joseph
May 20, 2026 4:28 PM - SEC Filing
Form 4 Larimar Therapeutics, For: May 19 Filed by: THOMAS FRANK E
May 20, 2026 4:25 PM - SEC Filing
Form 4 Larimar Therapeutics, For: May 19 Filed by: Hamilton Thomas Edward
May 20, 2026 4:22 PM - SEC Filing
Form 8-K Larimar Therapeutics, For: May 19
May 19, 2026 4:28 PM - SEC Filing
Larimar Therapeutics (LRMR) Reiterated at Market Outperform by Citizens
May 15, 2026 5:03 AM - StreetInsider
Form SCHEDULE 13G/A Larimar Therapeutics, Filed by: Blue Owl Capital Holdings LP
May 14, 2026 4:24 PM - SEC Filing
Form 10-Q Larimar Therapeutics, For: Mar 31
May 14, 2026 4:19 PM - SEC Filing
Larimar Therapeutics, Inc. (LRMR) Tops Q1 EPS by 22c
May 14, 2026 7:34 AM - StreetInsider
Form 8-K Larimar Therapeutics, For: May 14
May 14, 2026 7:03 AM - SEC Filing
Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update
May 14, 2026 7:01 AM - Globe NewsWire
Form SCHEDULE 13G/A Larimar Therapeutics, Filed by: MILLENNIUM MANAGEMENT LLC
April 30, 2026 6:17 PM - SEC Filing
Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich’s Ataxia
April 30, 2026 4:05 PM - Globe NewsWire
Full Article List